(Q50644764)

17 March 2018

title

Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. (English)

1 reference

17 March 2018

2

Paul Devroey

1 reference

17 March 2018

author name string

Asimina Tavaniotou

series ordinal

1

1 reference

17 March 2018

publication date

1 September 2006

1 reference

17 March 2018

Reproductive BioMedicine Online

published in

1 reference

17 March 2018

volume

13

1 reference

17 March 2018

issue

3

1 reference

17 March 2018

page(s)

326-330

1 reference

17 March 2018

Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertil

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Induction of Luteolysis in the Human with a Long-Acting Analog of Luteinizing Hormone-Releasing Factor

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Disappearance of exogenously administered human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Establishing full-term human pregnancies using cleaving embryos grown in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Disparate effects of endogenous and exogenous oestradiol on luteal phase function in women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Suppression of serum levels of luteinizing hormone by short- and long-loop negative feedback in ovariectomized women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Positive and negative feed-back effect of progesterone on luteinizing hormone secretion in post-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Effect of human chorionic gonadotropin on luteal luteinizing hormone concentrations in natural cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Endometrial integrin expression in the early luteal phase in natural and stimulated cycles for in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

Controlled natural cycle IVF with antagonist use and blastocyst transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961435-6

7 January 2021

10.1016/S1472-6483(10)61435-6

Identifiers

DOI

1 reference

17 March 2018

1 reference

17 March 2018